Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology has announced a special dividend of Contingent Value Rights (CVRs) to shareholders, allowing them to receive net proceeds from the sale of its legacy biosimilar assets. This move completes the company's transformation into a focused, innovative immuno-oncology company. The CVRs will be non-transferable and will expire on October 7, 2028, with payments contingent on the successful monetization of these biosimilar assets.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
This article reports on a Form 8K filing by Coherus BioSciences Inc for August 17. The brief piece primarily serves as an announcement for the filing, linking to Reuters for more details. It also includes general market data and other popular news headlines.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
Investing.com reports that Coherus BioSciences Inc. filed a Form 8K for August 17th. The article provides this basic information along with market data, news headlines, and various financial tools available on the Investing.com platform. Coherus BioSciences (CHRS) stock is noted with a +16.52% change.
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com
This article reports on a Form 8K filing by Coherus BioSciences Inc. for August 17. The brief announcement from Investing.com indicates that the filing was made on this date. Coherus BioSciences Inc. (CHRS) saw a stock price change of -4.17%.
Coherus BioSciences, Inc. (CHRS) stock price, news, quote and history
Coherus Oncology, Inc. (CHRS), formerly Coherus BioSciences, Inc., is a biopharmaceutical company focused on researching, developing, and commercializing immunotherapies for cancer. The article provides a detailed financial overview, including stock performance, key metrics like market capitalization and P/E ratio, and analyst ratings. It also lists the company's product pipeline, collaboration agreements, and comparative data with other biotechnology firms.
Coherus Oncology, Inc. (CHRS) Stock Price, News, Quote & History
This article provides a detailed overview of Coherus Oncology, Inc. (CHRS), including its current stock price, recent performance, company profile, and financial data. As of the market open, CHRS was trading at $1.3250, up 4.74%. The company, which recently changed its name from Coherus BioSciences, Inc., focuses on researching, developing, and commercializing immunotherapies for cancer, with products like UDENYCA and LOQTORZI.
Coherus Oncology, Inc. (CHRS) stock price, news, quote and history
Coherus Oncology, Inc. (CHRS) stock is trading at $1.3250, up 4.74%, with a market capitalization of $204.381 million. The biopharmaceutical company focuses on developing and commercializing immunotherapies for cancer, including products like UDENYCA and LOQTORZI. Analyst estimates a 1-year target price of $7.80 for the stock.
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall
Coherus Oncology Inc. reported a narrower-than-expected loss for Q2 2026, beating EPS estimates, but revenue fell slightly short of Wall Street's forecast, causing shares to fall in after-hours trading. The company's main oncology product, LOQTORZI, saw increased net sales and new patient starts, and Coherus is focused on ongoing clinical trials for tagmokitug and casdozokitug with anticipated data readouts later in 2026. Despite a mixed quarter with strong cost control but a revenue miss, the company maintains its full-year operating expense and LOQTORZI revenue guidance, expecting significant future growth for LOQTORZI.
Coherus Oncology Q2 2026 Earnings: LOQTORZI Growth Narrows the Loss
Coherus Oncology reported fiscal Q2 2026 net revenue of $14.3 million, a 40% increase year-over-year, driven primarily by LOQTORZI sales. The company narrowed its diluted loss per share to $0.22, largely due to LOQTORZI volume growth and reduced operating expenses. However, net cash used in operating activities increased to $62.1 million, and the company plans for several pipeline readouts in the second half of 2026.
Coherus BioSciences Inc (CHRS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Coherus BioSciences Inc (CHRS), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 2.69, ranking 118 out of 156 in the Pharmaceuticals industry, with a beta of 0.99 indicating underperformance in upward markets and smaller declines in downward markets. Key metrics like VaR, maximum drawdown, volatility, Sharpe Ratio, and liquidity indicators are presented to offer a comprehensive view of its investment risk profile.
Coherus BioSciences Inc (CHRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Coherus BioSciences Inc (CHRS), detailing its price momentum score of 4.09 and its position within the Pharmaceuticals industry. It identifies key support and resistance levels for the stock, indicating suitability for range-bound swing trading. The analysis also includes a breakdown of various technical indicators and moving averages, offering a comprehensive view of the stock's current technical status.
Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 7.59 within the Pharmaceuticals industry. The company's P/E ratio is 0.86, significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Coherus BioSciences Inc (CHRS) Institutional Confidence
Coherus BioSciences Inc (CHRS) has an institutional shareholding score of 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 35.13%, marking a significant quarter-over-quarter decrease of 49.78%. James Simons is listed as the largest institutional shareholder, holding 0.22% of outstanding shares.
Lobbying Update: $95,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed
A recent Lobbying Disclosure Act filing revealed that COHERUS BIOSCIENCES INC. engaged in $95,000 worth of lobbying during Q2 2026. The lobbying efforts focused on issues like oncology, Medicare coverage, domestic drug production, and supply chain security. Additionally, the article highlights recent hedge fund activity in CHRS stock, showing significant institutional investment.
CHRS|Coherus BioSciences Inc|Price:1.465|Chg%:+0.055
Coherus BioSciences Inc., now Coherus Oncology, Inc., is a commercial-stage oncology company focused on treating various cancers with its approved PD-1 inhibitor LOQTORZI and a pipeline of clinical candidates like CHS-114 and Casdozokitug. The article details the company's profile, including executives and financial data, highlighting UDENYCA as its primary revenue source. As of Q1 2026, 291 institutions hold CHRS shares, accounting for 35.13% of total shares.
Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings
The article provides a detailed breakdown of Coherus BioSciences Inc.'s (CHRS) shareholder structure, listing major individual and institutional holders. It also categorizes shareholders by type (e.g., Investment Advisor, Hedge Fund) and shows trends in institutional shareholding and activity over several quarters. Finally, it lists ETFs with reported holdings of CHRS.
Coherus BioSciences Inc (CHRS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Coherus BioSciences Inc (CHRS) stock, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and lists basic market data such as market capitalization and P/E ratio.
Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), segmenting its income by business product and geographic region as of April 6. The data shows that UDENYCA is the primary revenue driver, contributing 99.24% of the reported revenue, with the United States accounting for the majority of regional revenue.
Coherus BioSciences Inc (CHRS) Financial Health: Profitability & Balance Sheet Analysis
Coherus BioSciences Inc (CHRS) currently holds a financial score of 6.23, ranking 143 out of 155 in the Pharmaceuticals industry, indicating stable financial health but low operating efficiency. The company recently reported a quarterly revenue of $12.31M, marking a 61.99% year-over-year increase, and a net profit increase of 32.25% year-over-year. However, much of the detailed financial data, including cash and cash equivalents, total assets, and free cash flow, have not yet been disclosed by the company.
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020
Coherus BioSciences Inc (CHRS) shows relatively healthy fundamentals and high growth potential, though its stock price is expected to trend down in the medium term. The company's valuation is considered fair, ranking 97 out of 155 in the Pharmaceuticals industry, with strong institutional ownership. Analysts have rated it a Buy, with a highest price target of $7.25, indicating a significant upside potential despite recent weak market performance.
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook
Coherus BioSciences (CHRS) stock is trading lower due to declining revenue from its biosimilar Udenyca and a challenging market. The company reported a significant revenue drop in 2023 and Q1 2024, alongside ongoing net losses, though Q1 2024 showed some narrowing of losses. Coherus is pivoting towards immuno-oncology with toripalimab and diversifying its biosimilar portfolio with products like Cimerli and Yusimry to offset Udenyca's erosion, while managing its cash reserves.
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues
Coherus BioSciences (CHRS) stock is trading near recent lows due to declining biosimilar revenue and a strategic pivot towards oncology. The company reported a significant drop in fiscal 2023 revenue and widening net losses, reflecting intense competition in its legacy biosimilar products. Despite the financial headwinds, Coherus is investing heavily in its immuno-oncology pipeline, particularly toripalimab, aiming to establish a new growth-oriented franchise, although this transition carries execution risks and near-term profitability constraints.
Coherus BioSciences stock stays supported by oncology focus
Coherus BioSciences (CHRS) stock reflects the company's strategic shift towards immuno-oncology while maintaining a biosimilar portfolio. Investors are closely monitoring revenue generation from commercialized biosimilars, the company's cash position, and advancements in its oncology pipeline, which includes checkpoint inhibitors and antibody-based therapies. This strategy aims to leverage biosimilar revenues to fund the higher-risk, higher-reward oncology development, transforming its earnings profile.
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing
Coherus BioSciences is a biopharmaceutical company listed on Nasdaq, specializing in biosimilar and immuno-oncology products. The company aims to provide lower-cost alternatives to established branded therapies and is also developing innovative cancer treatments. Investors are watching its progress in both biosimilar market penetration and immuno-oncology clinical development.
CHRS Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Coherus Oncology, Inc. (CHRS) stock, outlining analysts' predictions and historical performance data. It details the company's current stock price, market capitalization, volatility, and future earnings estimates, alongside historical highs and lows. The information is presented as a financial overview for potential investors, noting that it is not investment advice.
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus Oncology and Zumutor Biologics have announced a clinical collaboration and supply agreement for a Phase 1 trial evaluating ZM008, an anti-LLT1 monoclonal antibody, in combination with Coherus's PD-1 inhibitor, LOQTORZI. The study will enroll patients with various solid tumors, with the goal of expanding LOQTORZI indications and strengthening clinical data. This partnership aims to leverage complementary immune pathways to treat hard-to-treat cancers and identify predictive biomarkers for personalized therapies.
Coherus BioSciences Inc (CHRS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Coherus BioSciences Inc (CHRS), noting its current valuation score of 9.20, which ranks 44th in the Pharmaceuticals industry. It highlights that the company's current P/E ratio is 0.85, significantly lower than its recent high but higher than its recent low. The article also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Coherus BioSciences Inc (CHRS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Coherus BioSciences Inc (CHRS), identifying major individual and institutional holders, along with their respective proportions. It also presents a breakdown of shareholder types, including investment advisors, corporations, and hedge funds. Furthermore, the piece provides a
Coherus BioSciences Inc (CHRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Coherus BioSciences Inc (CHRS), categorizing its revenue by business segment and by region. For the reported period, UDENYCA accounted for the vast majority of revenue at 99.24%, followed by CIMERLI and YUSIMRY. Geographically, all reported revenue came from the United States.
Coherus BioSciences Inc (CHRS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Coherus BioSciences Inc (CHRS) has an earnings forecast score of 8.57, ranking 27th in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for CHRS, with a "Buy" rating based on the consensus of seven analysts. The company's expected revenue for the next quarter is $14.60M, and EPS is forecasted at -$0.14.
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young By Investing.com
Coherus Oncology has appointed PricewaterhouseCoopers LLP (PwC) as its new independent auditor, replacing Ernst & Young LLP, effective June 12, 2026. The change follows the dismissal of Ernst & Young by the Audit Committee, with Coherus Oncology stating no disagreements on accounting principles that would have required mention in past audit reports, despite a previously remediated material weakness in internal control. This announcement comes amid other recent company news, including a Q1 2026 EPS alignment but revenue shortfall, and the election of new Class III directors at its annual meeting.
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young
Coherus Oncology has announced the dismissal of Ernst & Young LLP as its independent auditor, effective June 12, and the appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026. The company stated that there were no disagreements on accounting principles or audit procedures with Ernst & Young, although a material weakness in internal controls from 2024 was remediated by 2025 year-end. This change follows recent financial news, including the company's Q1 2026 earnings and the election of new Class III directors.
[8-K] Coherus Oncology, Inc. Reports Material Event
Coherus Oncology, Inc. filed an 8-K report announcing a change in its independent auditing firm. On June 12, 2026, the company dismissed Ernst & Young LLP and appointed PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026, subject to standard acceptance procedures. EY confirmed no adverse opinions or disagreements in their past audits, although a material weakness in internal controls for inventory reconciliations was previously reported and has since been remediated.
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant
Coherus Oncology director Ali J. Satvat was granted 30,000 restricted stock units (RSUs) and a stock option for 60,000 shares on June 5, 2026. The RSUs vest 100% on June 3, 2027, and the stock option, with an exercise price of $1.45, becomes fully exercisable on June 3, 2027. Both awards are contingent on his continued service with the company.
[Form 4] Coherus Oncology, Inc. Insider Trading Activity
This article reports on insider trading activity at Coherus Oncology, Inc. (CHRS) from a Form 4 filing. It details two transactions by insider Ryan Michael Lee, involving the grant of 30,000 shares of common stock and 60,000 stock options, both vesting over time. The filing impact and sentiment are classified as neutral.
Coherus Oncology shareholders approve director elections and equity plan changes
Coherus Oncology shareholders held their 2026 Annual Meeting, electing two Class III directors, Dennis M. Lanfear and Mats L. Wahlström, and ratifying Ernst & Young LLP as their independent public accounting firm. They also approved a non-binding advisory resolution on executive compensation, reduced the exercise price of certain stock options, and increased shares reserved for their equity incentive plan. These decisions follow the company's recent Q1 2026 earnings report, which met EPS expectations but showed a revenue shortfall.
Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing
Coherus Oncology, Inc. shareholders approved all proposals at their 2026 annual meeting, including the election of Class III directors, ratification of Ernst & Young LLP as auditor, and a non-binding Say-on-Pay resolution. Key equity-related approvals included a reduction in the exercise price of certain outstanding stock options and an increase in shares reserved under the Amended and Restated 2014 Equity Incentive Award Plan. These approvals are expected to affect future dilution and employee incentives for the company.
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59
Coherus Oncology, Inc. announced the repricing of 3.2 million stock options for President & CEO Dennis M. Lanfear to an exercise price of $1.59 per share. These new options replace older ones with significantly higher exercise prices, a move approved by stockholders on May 29, 2026, and contingent on Lanfear remaining with the company through May 29, 2027. This adjustment aims to re-align his compensation with the current share price and provide new incentives.
Coherus Biosciences Announces 2026 Stockholder Meeting Results
Coherus Biosciences (CHRS) announced the results of its 2026 Annual Meeting of Stockholders. Key outcomes include the election of Class III directors, ratification of Ernst & Young LLP as auditor, approval of executive compensation, and a reduction in the exercise price of certain stock options. Stockholders also authorized an increase in shares for its equity incentive plan to attract and retain talent.
Coherus Oncology shareholders approve director elections and equity plan changes
Coherus Oncology shareholders approved the election of two Class III directors, ratified the appointment of Ernst & Young LLP as their accounting firm, and approved executive compensation. Additionally, shareholders voted to reduce the exercise price of certain stock options and increase shares reserved under the 2014 Equity Incentive Award Plan. These decisions were made during their 2026 Annual Meeting of Stockholders, which included a partial adjournment for one proposal.
CHRS - Coherus Oncology Inc Stock Price and Quote
This article provides comprehensive stock information for Coherus Oncology Inc. (CHRS), including its latest stock price, financial overview, analyst ratings, and recent news. Key data points cover market capitalization, P/E ratios, EPS, sales figures, and insider/institutional ownership, alongside performance metrics across various timeframes. The news section highlights corporate activities like earnings calls, clinical collaborations, financial results, and strategic transformations, emphasizing the company's shift towards innovative cancer therapeutics.
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants
Coherus Oncology's CFO, Bryan J. McMichael, received new stock options on May 29, 2026, with an exercise price of $1.59 per share, totaling 220,000 shares. Simultaneously, previously granted options with higher exercise prices, ranging from $5.44 to $14.76 per share, were disposed of back to the issuer as part of a stockholder-approved repricing initiative. This repricing affects options previously priced at or above $5, aiming to reset them at the new $1.59 exercise price, contingent on the CFO's continued service through May 29, 2027.
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncology pipeline
Coherus BioSciences (CHRS) continues to experience high short interest and volatile trading as investors assess its oncology and biosimilar portfolios. The company, a US biotechnology firm, is strategically shifting towards high-margin oncology assets while managing its legacy biosimilar products. Investors are closely monitoring clinical trial data, regulatory milestones, and market dynamics to gauge the company's future financial performance and competitive position.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology reported its first-quarter 2026 financial results, highlighting LOQTORZI® net revenue of $11.8 million, a 61% increase year-over-year. The company also provided updates on its pipeline, including the completion of patient accrual for the 1L HCC Phase 2 clinical trial for casdozokitug and progress in the tagmokitug development program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
Coherus Oncology announced its first-quarter 2026 financial results, reporting $11.8 million in LOQTORZI net revenue, a 61% increase year-over-year. The company provided updates on its oncology pipeline, including the completion of patient accrual for the casdozokitug Phase 2 trial and advancements in the tagmokitug program. Coherus ended the quarter with $167.0 million in cash, cash equivalents, and marketable securities.
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast
Coherus BioSciences reported Q1 2026 revenue of $12.31 million, falling short of the $14.43 million forecast, but its EPS of -$0.25 met expectations. Despite the revenue miss, the company's shares rose 11.43% in after-hours trading, driven by investor optimism about future growth and strategic initiatives. Key products like LOQTORZI showed significant year-over-year growth, and management expects a rebound from weather-related impacts in Q2 2026.
Coherus BioSciences Inc CHRS
This page provides an overview of Coherus BioSciences Inc. (CHRS) stock, including its current price, market cap, and P/E ratio. It shows the stock closed at $1.950 with an 11.43% increase on May 11th. The platform also offers various financial analysis tools and news for investors.
Coherus (CHRS) Reports Q1 Revenue Below Expectations
Coherus BioSciences (CHRS) announced Q1 revenue of $12.31 million, falling short of the anticipated $14.34 million. The company, which has a GF Score™ of 51/100, is focusing on its LOQTORZI product for neuroendocrine prostate cancer and other pipeline products, despite facing challenges in financial strength and profitability. Investors are advised to be cautious due to the revenue shortfall, low GF Score™, and minimal insider activity.
Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M
Coherus Oncology reported a notable increase in Q1 2026 revenue to $12.3 million from $7.6 million year-over-year, primarily driven by LOQTORZI sales totaling $11.8 million. The company successfully narrowed its GAAP net loss from continuing operations to $36.9 million and maintained a cash position of $167.0 million, signaling progress in its oncology transition while continuing development for key pipeline candidates like tagmokitug and casdozokitug.
Coherus Biosciences Inc (CHRS) Stock News & Articles
This page provides an overview of Coherus BioSciences Inc (CHRS), a biopharmaceutical company specializing in biosimilars and immuno-oncology treatments. It details the company's key products like UDENYCA, CIMERLI, and YUSIMRY, and highlights its strategic partnerships aimed at affordable healthcare solutions. The page also features a recent article discussing Wall Street analyst research calls, including one relevant to Coherus Oncology.
